In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co. (India) Pvt. Ltd.

Division of Eli Lilly & Co.
www.lillyindia.co.in

Latest From Eli Lilly & Co. (India) Pvt. Ltd.

Can Lilly's Olumiant Prickle Xeljanz In India?

Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
India Commercial

Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar

Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.

Asia Pacific Deals

Musical Chairs: Glenmark Set To See Two Big Exits As Ranbaxy Shuffles Key Roles

Large Indian drug companies are seeing changes in their top management as they take to marketing newer innovative brands.

BioPharmaceutical India

Deals Shaping the Medical Industry (09/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Eli Lilly & Co. India Pvt. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Contact Info
  • Eli Lilly & Co. (India) Pvt. Ltd.
    Phone: (91) 124 4753000
    Plot. #92, Sector 32, Institutional Area
    Gurgaon
    Haryana, 122001
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register